Netherlands Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

1.1 List of Figures
1.2 List of Tables

2.1 Executive Summary
2.2 Key Highlights - Facts about the Netherlands Healthcare Market
2.3 Key Highlights: Healthcare Startups in the Netherlands
2.4 Key Events: The Netherlands Healthcare Timeline, 2016-22
2.5 Key Events: The Netherlands Pharmaceutical Market
2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020-22
2.7 Key Events: Mergers and Acquisitions
2.8 Country Profile, the Netherlands, 2021

3.1 Pharmaceutical Market - Overview
3.2 Pharmaceutical Market - Exports
3.3 Pharmaceutical Market - Imports
3.4 Pharmaceutical Market - Supply Channels, the Netherlands
3.5 Pharmaceutical Market - Market Segments
3.6 Pharmaceutical Market - Market Segments, Generics, the Netherlands
3.7 Pharmaceutical Market - Market Segments, Biologics and Biosimilars, the Netherlands
3.8 Pharmaceutical Market - Market Segments, OTC Medicines, the Netherlands
3.9 COVID-19 Epidemiology, the Netherlands
3.10 COVID-19 Impact and Developments in the Healthcare Market, the Netherlands
3.11 Pharmaceutical Market - Major Players

4.1 Medical Device Market - Overview
4.2 Medical Device Market - Major Segments
4.3 Medical Device Market - Hospital Supplies Market
4.4 Medical Device Market - Cardiovascular Devices Market
4.5 Medical Device Market - Orthopedic Devices Market
4.6 Medical Device Market - General Surgery Market
4.7 Medical Device Market - Wound Care Management Market
4.8 Medical Devices Market - Diagnostic Market
4.9 Medical Devices Market - Major Players

5.1 Drivers
5.2 Barriers

6.1 Deal Analysis: Pharmaceutical Market, the Netherlands, 2021-22
6.2 Deal Analysis: Medical Device Market, the Netherlands, 2021-22

7.1 HealthTech Landscape, the Netherlands
7.2 HealthTech Deals Landscape, the Netherlands
7.3 Key HealthTech Deals, the Netherlands
7.4 Adoption of Technology in Healthcare, the Netherlands
7.5 Digital Statistics, the Netherlands
7.6 Regulatory Scenario Covering Use of Technology in Healthcare, the Netherlands
7.7 HealthTech Landscape: Benefits and Risks, the Netherlands

8.1 Overview of Healthcare System, the Netherlands
8.2 Reimbursement Landscape, the Netherlands
8.3 Reimbursement Process, the Netherlands
8.4 Overview of Insurance Providers, the Netherlands
8.5 Healthcare Spending and Prescription Drug Price Trends, the Netherlands
8.6 Pricing Policies, the Netherlands
8.7 Market Access: Key Events Timeline, the Netherlands, 2010-21
8.8 Regulatory Landscape, the Netherlands
8.8.1 Marketing Authorization for Pharmaceutical Products, the Netherlands
8.8.2 Marketing Authorization for Pharmaceutical Products (Centralized Procedure), the Netherlands
8.8.3 Marketing Authorization for Pharmaceutical Products (Decentralized Procedure), the Netherlands
8.8.4 Marketing Authorization for Pharmaceutical Products (Mutual Recognition Procedure), the Netherlands
8.8.5 Marketing Authorization for Medical Devices, the Netherlands
8.8.6 Intellectual Property Rights, Patent, the Netherlands
8.8.7 Intellectual Property Rights, Trademark, the Netherlands
8.8.8 Clinical Trial Regulation Process, the Netherlands
8.8.9 Pharmaceutical Clinical Trials Landscape, the Netherlands
8.8.10 Medical Devices Clinical Trials Landscape, the Netherlands
8.8.11 Pharmaceutical Import and Export, the Netherlands
8.8.12 Pharmaceutical Advertising Regulations, the Netherlands
8.8.13 Pharmacy Regulations, the Netherlands
8.8.14 Labeling and Packaging Regulations, the Netherlands

9.1 The Netherlands Healthcare Policy Highlights
9.2 Healthcare Facilities, the Netherlands
9.3 Healthcare Resources, the Netherlands
9.4 Life Expectancy and Immunization Rate, the Netherlands
9.5 Environmental Health, the Netherlands
9.6 Healthcare Personnel, the Netherlands
9.7 Disease Burden, the Netherlands
9.8 Healthcare Expenditure, the Netherlands

13.1 Research Methodology
13.1.1 Coverage
13.1.2 Secondary Research
13.1.3 Forecasts
13.2 Bibliography
13.3 About the Publisher
13.4 Contact the Publisher
13.5 Disclaimer

Table 1: Approved biosimilars, EU, 2021-22
Table 2: COVID-19 indicators (number of cases), global and the Netherlands, 2022
Table 3: COVID-19-related travel restrictions, the Netherlands, 2020-22
Table 4: Approved vaccines, the Netherlands, 2022
Table 5: COVID-19 vaccine trials, the Netherlands, 2022
Table 6: COVID-19 IVD products (October 2021 - October 2022), the Netherlands, 2021-22
Table 7: Medical devices market, major segments ($M), the Netherlands, 2021
Table 8: Hospital supplies market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021
Table 9: Cardiovascular devices market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021
Table 10: Orthopedic devices market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021
Table 11: General surgery devices market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021
Table 12: Wound care management market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021
Table 13: Classification of medical devices, the Netherlands, 2022
Table 14: Trade fairs, the Netherlands, 2022

Figure 1: Pharmaceutical market, revenue ($B and €B), the Netherlands, 2015-21
Figure 2: Medical devices market, revenue ($B), the Netherlands, 2016-21
Figure 3: Healthcare start-ups in the Netherlands, 2022
Figure 4: Country profile, the Netherlands, 2021
Figure 5: Pharmaceutical market, revenue ($B and €B), the Netherlands, 2015-21
Figure 6: Pharmaceutical market, revenue forecast ($B and €B), the Netherlands, 2022-27
Figure 7: Pharmaceutical exports ($B), the Netherlands, 2014-21
Figure 8: Top export partners, the Netherlands, 2021
Figure 9: Pharmaceutical imports ($B), the Netherlands, 2014-21
Figure 10: Top import partners, the Netherlands, 2021
Figure 11: Pharmaceutical supply channel, the Netherlands, 2022
Figure 12: Members of BOGIN, the Netherlands, 2022
Figure 13: OTC market revenue ($B), the Netherlands, 2013-21
Figure 14: OTC market by sub-categories of drugs, revenue ($M), the Netherlands, 2021
Figure 15: COVID-19 cases, the Netherlands, 2020-22
Figure 16: COVID-19 deaths, the Netherlands, 2020-22
Figure 17: COVID-19 fiscal stimulus timeline, the Netherlands, 2020-21
Figure 18: COVID-19 stringency index (based on the share of people who are vaccinated), the Netherlands, 2020-22
Figure 19: COVID-19 containment and health index, the Netherlands, 2020-22
Figure 20: COVID-19 vaccine booster doses administration, number of vaccine doses administered per 100 people, the Netherlands, 2021-22
Figure 21: cumulative number of total vaccination doses administered, the Netherlands, 2021-22
Figure 22: top COVID-19 clinical trials sponsors by trial count, the Netherlands, 2021-22
Figure 23: COVID-19 clinical trials count by trial status, the Netherlands, 2021-22
Figure 24: Medical devices market, revenue ($b), the Netherlands, 2016-21
Figure 25: Medical devices market, revenue forecast ($B), the Netherlands, 2022-27
Figure 26: Medical devices market, major segments (%), the Netherlands, 2021
Figure 27: Hospital supplies market, revenue ($M), the Netherlands, 2017-27
Figure 28: Hospital supplies market, the Netherlands, market share of major players (%), 2021
Figure 29: Cardiovascular devices market, revenue ($M), the Netherlands, 2017-27
Figure 30: Cardiovascular devices market, the Netherlands, market share of major players (%), 2021
Figure 31: Orthopedic devices market, revenue ($M), the Netherlands, 2017-27
Figure 32: Orthopedic devices market, the Netherlands, market share of major players (%), 2021
Figure 33: General surgery devices market, revenue ($M), the Netherlands, 2017-27
Figure 34: General surgery devices market, the Netherlands, market share of major players (%), 2021
Figure 35: Wound care management market, revenue ($M), the Netherlands, 2017-27
Figure 36: Wound care management market, the Netherlands, market share of major players (%), 2021
Figure 37: Diagnostic market, revenue ($M), the Netherlands, 2017-21
Figure 38: Diagnostic market, revenue ($M), the Netherlands, 2022-27
Figure 39: Medical devices market, revenue ($B) of Major Companies, the Netherlands, 2021
Figure 40: Deal value and deal count, pharmaceutical market, the Netherlands, 2021-22
Figure 41: Deal value and deal count subtypes, pharmaceutical market, the Netherlands, 2021-22
Figure 42: Deal value and deal count, quarterly, pharmaceutical market, the Netherlands, 2021-22
Figure 43: Top therapy areas by deal value ($M), pharmaceutical market, the Netherlands, 2021-22
Figure 44: Top therapy areas by deal count, pharmaceutical market, the Netherlands, 2021-22
Figure 45: M&A deals by quarter, pharmaceutical market, the Netherlands, 2021-22
Figure 46: VC deals by quarter, pharmaceutical market, the Netherlands, 2021-22 (by value and by number)
Figure 47: Deal value and deal count, medical devices market, the Netherlands, 2021-22
Figure 48: Deal value and deal count subtypes, medical devices market, the Netherlands, 2021-22
Figure 49: Deal value and deal count, quarterly, medical devices market, the Netherlands, 2021-22
Figure 50: Top equipment sectors by deal value ($M), medical devices market, the Netherlands, 2021-22
Figure 51: Top equipment sectors by deal count, medical devices market, the Netherlands, 2021-22
Figure 52: M&A deals by quarter, medical devices market, the Netherlands,
2021-22 (by value and by number)
Figure 53: VC deals by quarter, medical devices market, the Netherlands,
2021-22 (by value and by number)
Figure 54: Dutch digitalization strategy, the Netherlands, 2021
Figure 55: Strategic pillars of the national strategy on AI, the Netherlands, 2019
Figure 56: Deal value ($M) and deal count, healthtech, the Netherlands, 2021-22
Figure 57: Deal value ($M) and deal count by sector, healthtech, the Netherlands, 2021-22
Figure 58: GDPR compliance checklist, EU, 2022
Figure 59: Organization of the health system, the Netherlands, 2022
Figure 60: Drug reimbursement process, the Netherlands, 2022
Figure 61: Public and private insurance coverage (% of total population), the Netherlands, 2013-2020
Figure 62: OOP expenditure (% of total expenditure on health), the Netherlands, 2013-20
Figure 63: Annual rate of change (%), consumer price index, the Netherlands, 2014-21
Figure 64: Organization of MEB, the Netherlands, 2022
Figure 65: Centralized procedure, the Netherlands, 2022
Figure 66: Decentralized procedure, the Netherlands, 2022
Figure 67: Mutual recognition procedure, the Netherlands, 2022
Figure 68: European patent approval process, the Netherlands, 2022
Figure 69: Pharmaceutical clinical trial count by trial status, the Netherlands, 2021-22
Figure 70: Pharmaceutical clinical trial count by indication, the Netherlands, 2021-22
Figure 71: Pharmaceutical clinical trial count by phase, the Netherlands, 2021-22
Figure 72: Top five pharmaceutical clinical trial sponsors by count, the Netherlands, 2021-22
Figure 73: Medical devices clinical trial count by trial status, the Netherlands, 2021-22
Figure 74: Medical devices clinical trial count by indication, the Netherlands, 2021-22
Figure 75: Medical devices clinical trial count by market categories, the Netherlands, 2021-22
Figure 76: Top five medical devices clinical trial sponsors by count, the Netherlands, 2021-22
Figure 77: Contents of the outer label of pharmaceutical products, the Netherlands, 2022
Figure 78: Number of hospitals, the Netherlands, 2013-21
Figure 79: Number of diagnostic units, the Netherlands, 2013-21
Figure 80: Hospital beds (per 1,000 population), the Netherlands, 2013-21
Figure 81: Acute care hospital beds (per 1,000 population), the Netherlands, 2013-21
Figure 82: Psychiatric care hospital beds (per 1,000 population), the Netherlands, 2013-21
Figure 83: Life expectancy at birth (years), the Netherlands, 2013-21
Figure 84: Immunization rate (%), the Netherlands, 2013-21
Figure 85: PM2.5 (µg per m3), the Netherlands, 2013-19
Figure 86: CO2 emissions (million tons), the Netherlands, 2013-20
Figure 87: Physicians (per 1,000 population), the Netherlands, 2013-21
Figure 88: Pharmacists (per 1,000 population), the Netherlands, 2013-21
Figure 89: Dentists (per 1,000 population), the Netherlands, 2013-21
Figure 90: Nurses (per 1,000 population), the Netherlands, 2013-21
Figure 91: Major causes of mortality (per 100,000 population), the Netherlands, 2019
Figure 92: Major causes of male mortality (per 100,000 population), the Netherlands, 2019
Figure 93: Major causes of female mortality (per 100,000 population), the Netherlands, 2019
Figure 94: DALYs by major disease (per 100,000 population), the Netherlands, 2019
Figure 95: Healthcare expenditure as percentage of GDP (%), the Netherlands, 2013-21
Figure 96: Health expenditure share (% of current health spending), the Netherlands, 2013-21
Figure 97: Pharmaceutical spending (% of total health spending), the Netherlands, 2013-21
Figure 98: Healthcare expenditure components by function (% of total health expenditure), the Netherlands, 2020